Glycolipid Disialoganglioside-directed Antibody
- Glycolipid Disialoganglioside-directed Antibody
- Accession Number
Drug Drug Description Dinutuximab An immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Naxitamab A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
- Drugs & Drug Targets
Drug Target Type Dinutuximab GD2 disialoganglioside target Naxitamab GD2 disialoganglioside target